東方生物(688298.SH):美國市場新冠抗原自測試劑主要取決於西門子醫療的銷售能力
格隆匯1月14日丨東方生物(688298.SH)發佈股票交易異常波動公吿,2021年度,公司經營業績主要依賴於新型冠狀病毒抗原檢測試劑(含家庭自測)(“新冠抗原試劑”)在歐洲市場的銷售業績;2021年12月30日,公司新冠抗原自測試劑被美國FDA EUA授權SIEMENS HEALTHINEERS (“西門子醫療”)指定供應商,市場同類產品供應商較多,將面臨激烈的市場競爭風險,截至公吿披露日,對公司經營業績沒有影響。
公司未來經營業績能否繼續保持高速增長,存在重大不確定性,主要取決於全球新冠疫情防控進展,以及各國對新冠檢測產品的選擇,公司產品市場競爭力和渠道銷售能力(其中,美國市場新冠抗原自測試劑主要取決於西門子醫療的銷售能力)以及公司產能情況,常規業務的未來發展情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.